(March 17): AstraZeneca plc, the UK drugmaker, agreed to buy the Belgian biotech EsoBiotec for as much as US$1 billion (RM4.44 billion) to further boost its cancer capabilities.
AstraZeneca will pay US$425 million upfront and may spend up to US$575 million more in development and regulatory milestones, the companies said Monday.
EsoBiotec’s platform has the potential to transform cell therapy, according to AstraZeneca, by empowering the immune system to attack cancers. It uses targeted viruses to engineer immune cells directly within a person’s body and could allow treatment to be delivered in minutes rather than the current standard of several weeks.
EsoBiotec will become a subsidiary of AstraZeneca and maintain operations in Belgium. The transaction is expected to close in the second quarter.
In a separate cancer deal announced Monday, AstraZeneca agreed to a licensing deal for multiple oncology assets from Alteogen Inc.
Uploaded by Arion Yeow
- Malaysia hit with 24% US reciprocal tariff effective April 9
- Malaysia won’t retaliate, will negotiate with US on tariffs — Miti
- Apple production hubs, including Malaysia, hit by tariffs
- Glovemakers rebound as investors see competitive advantages
- Trump’s tariffs on Asean: Nothing to dread, everything to fear
- Tiny Australian outposts, including some with no people, targeted by Trump tariffs
- China detains three Filipinos for alleged spying as ties fray
- Trump signs order ending 'de minimis' duty-free treatment for low-value parcels from China
- Trump tariffs are ‘disaster’ for the world’s poorest countries
- Israel to formulate 'necessary steps' in response to US tariffs, finance minister says